Public Employees Retirement System of Ohio Buys Shares of 214,400 Qiagen (NYSE:QGEN)

Public Employees Retirement System of Ohio acquired a new stake in Qiagen (NYSE:QGEN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 214,400 shares of the company's stock, valued at approximately $9,717,000. Public Employees Retirement System of Ohio owned about 0.09% of Qiagen at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock worth $39,000 after buying an additional 243 shares during the last quarter. CWM LLC lifted its position in Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company's stock valued at $103,000 after acquiring an additional 269 shares during the last quarter. Zurich Insurance Group Ltd FI boosted its stake in Qiagen by 5.7% in the third quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company's stock valued at $239,000 after acquiring an additional 287 shares in the last quarter. National Bank of Canada FI boosted its stake in Qiagen by 1.2% in the third quarter. National Bank of Canada FI now owns 25,636 shares of the company's stock valued at $1,155,000 after acquiring an additional 308 shares in the last quarter. Finally, Atria Investments Inc increased its position in shares of Qiagen by 6.0% during the third quarter. Atria Investments Inc now owns 7,632 shares of the company's stock worth $348,000 after purchasing an additional 433 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

NYSE QGEN traded down $0.19 on Thursday, hitting $45.97. The stock had a trading volume of 613,864 shares, compared to its average volume of 1,137,470. The company's 50-day moving average is $43.13 and its two-hundred day moving average is $43.68. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The stock has a market cap of $10.49 billion, a price-to-earnings ratio of 118.21, a P/E/G ratio of 3.37 and a beta of 0.35. Qiagen has a one year low of $39.03 and a one year high of $47.44.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Jefferies Financial Group restated a "buy" rating and set a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research note on Tuesday. HSBC lowered shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Qiagen to a "hold" rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Qiagen has a consensus rating of "Moderate Buy" and an average price target of $51.15.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.